What happened with MDXH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MDxHealth SA helps physicians decide whether men need a prostate biopsy and how to treat diagnosed prostate cancer. Most revenue comes from Confirm mdx, which examines previously biopsied tissue for signs of cancer that may have been missed, and GPS mdx, which analyzes gene activity in tumor tissue to guide treatment decisions. Its Exo mdx urine test helps inform initial biopsy decisions, while Resolve mdx identifies urinary tract infection pathogens and potential antibiotic options.
The business is concentrated in the United States, where its sales team works primarily with urologists and their practices. Physicians order the tests, MDxHealth performs the laboratory work, and it bills health insurers, government healthcare programs or patients. Without an applicable payer policy or contract, it seeks payment case by case; collections can take months or never arrive.
Medicare supplies a substantial share of revenue, so coverage and reimbursement are central to the business, alongside physicians’ willingness to order its tests. MDxHealth must maintain laboratory certification and required licenses both to perform testing and to bill government and commercial payers.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
MDxHealth SA's results hinge on urologists adopting its tests and Medicare reimbursement, while Beckman Coulter's Prostate Health Index adds competition over biopsy-risk assessment.
Veracyte, Inc.'s Decipher Prostate competes with MDxHealth SA's GPS mdx to help men with localized prostate cancer choose treatment or active surveillance through genetic testing of tumor tissue. Watch adoption of Decipher Prostate, a commercial priority for Veracyte, rather than its broader test revenue, for signs of competition facing GPS mdx.
Myriad Genetics Inc's Prolaris competes with MDxHealth SA's GPS mdx by testing prostate-cancer tissue to help men choose treatment or active surveillance. Prolaris-specific news is the relevant signal for GPS mdx; Myriad's portfolio also spans other cancer tests, women's health and mental health.
Labcorp Holdings Inc.'s acquired 4Kscore competes with MDxHealth SA's urine-based Exo mdx for assessing aggressive prostate-cancer risk before biopsy. Watch 4Kscore: it combines blood markers with clinical information to assess men without a previous prostate-cancer diagnosis before an initial or repeat biopsy.
Onconetix, Inc.'s blood-based Proclarix offers an alternative to MDxHealth SA's urine-based Exo mdx when PSA results leave prostate-biopsy decisions uncertain, though Proclarix currently sells in Europe. Watch its planned U.S. launch through a Labcorp license agreement, which remains a plan rather than current U.S. sales.
Labcorp Holdings Inc. earningsLH
Labcorp’s report can show whether clinicians are using 4Kscore more to assess prostate-cancer risk, competing with MDxHealth’s Exo mdx for the same pre-biopsy decision.
Look for any separately reported change in 4Kscore use or revenue; Labcorp’s overall diagnostics growth is not evidence of demand for this test. Rising 4Kscore use would show strong demand for pre-biopsy risk assessment and a sharper competitive challenge for Exo mdx; weak or slowing use would mean less evidence of that pressure, not proof that Exo mdx is benefiting.
Fed Interest Rate Decision
The Fed’s decision signals the direction of U.S. interest rates; if it lifts SOFR above the loan’s 2.50% floor, MDxHealth pays more interest on its OrbiMed borrowing, leaving less cash for testing operations.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s decision is higher than expected, higher rates may lift SOFR above the floor, increasing MDxHealth’s OrbiMed interest costs and reducing cash left to pay for operations.
If it comes in below expectations
If the Fed’s decision is lower than expected, lower rates may reduce SOFR while it remains above the floor, cutting MDxHealth’s OrbiMed interest costs and leaving more cash for operations.
Veracyte, Inc. earningsVCYT
Veracyte’s report can show whether Decipher Prostate is gaining use in treatment or active-surveillance decisions for localized prostate cancer, competing with MDxHealth’s GPS mdx for the same tissue-testing need.
Focus on any reported adoption of Decipher Prostate, not changes in Veracyte’s overall test revenue as a substitute for this prostate test’s performance. Rising adoption would mean more clinicians are using tissue testing to guide treatment or active surveillance, sharpening competition for GPS mdx; weak or slowing adoption would offer less evidence of that pressure, not show that GPS mdx use is rising.
